References in periodicals archive ?
Commenting on the procedure, Buchbinder said, "With the in-stent restenosis rate of zero achieved using the RDX(TM) Radiation Delivery Catheter in the BRITE I study, I am very pleased to offer this exciting new treatment to patients who previously had few options.
Jeff Thiel, president and CEO of Radiance commented: "With the results that we have experienced in the BRITE I Trial we are excited about the opportunity to prove the efficacy of the RDX System in a broader clinical trial.
At the American Heart Association meeting in November 2000 Radiance announced the results of the BRITE I trial.
Nasdaq:RADX) Wednesday announced that the results of the BRITE I Clinical Study were presented at the annual American Heart Association (AHA) meeting being held this week in New Orleans.
Independent Angiographic Laboratory Confirms Zero Restenosis in BRITE I Study
Waksman reported that in the 26 patients treated in the BRITE I study, only one patient, or 3.
In combining the BRITE I study patients with in-stent restenosis patients from the company's European BETTER (Beta Radiation Trial to Eliminate Restenosis) Study, in a total of 47 in-stent restenosis patients followed up for six months, a repeat interventional procedure was required in only two patients, or 4.
the Principal Investigator of both the BRITE I and BRITE II Studies said, "The BRITE study utilizing the RDX(TM) Coronary Radiation Delivery System demonstrates the lowest restenosis rate ever reported (3.
Waksman will present a further summary of the BRITE I results at the TCT Plenary Sessions on Saturday, Oct.
US Brite is an industry leading lighting company that offers LED lighting products, services and expertise to both national and international clients.
InterVoice- Brite is one of the markets' leading communications and e-commerce ASPs with over 7 million subscribers already supported on its multi-media managed services.
Brite is a world leader in providing enhanced telecommunications systems and interactive information systems.